期刊文献+

胺碘酮联合小剂量氟伐他汀治疗阵发性房颤的临床观察 被引量:3

下载PDF
导出
摘要 目的评价胺碘酮联合小剂量氟伐他汀治疗阵发性房颤的疗效和安全性。方法将78例阵发性心房颤动患者随机分为胺碘酮组(n=35)和胺碘酮+氟伐他汀组(n=43),治疗随访时间为6个月,研究的一级终点是房颤复发。比较两组治疗后的窦性心律维持率。结果治疗6个月后胺碘酮组有效率为71.4%,胺碘酮+氟伐他汀组有效率为78.4%(P<0.05),组间差异有统计学意义。结论胺碘酮联合小剂量氟伐他汀治疗阵发性房颤安全有效,还可能减少心脑血管病的发生。
作者 谢百福
出处 《中国实用医药》 2007年第33期131-132,共2页 China Practical Medicine
  • 相关文献

参考文献5

  • 1戚文航.中国部分地区心房颤动住院病例回顾性调查[J].中华心血管病杂志,2003,31(12):913-916. 被引量:380
  • 2[2]Kumagai K,Nakashima H,Saku K.The HMG-CoA reductase inhibitoratorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis mode.Res,2004,62 (1):105-111.
  • 3[3]Shiroshita-Takeshita A,Schram G,Lavoie J,et al.Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrialtachycardia remodeling in dogs.Circulation,2004,110(16):2313-2319.
  • 4[4]Siu CW,Lau CP,Tse HF.Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion.Am J Cardiol,2003,92(11):1343-1345.
  • 5王薇,赵冬,刘静,曾哲淳,孙佳艺,刘军,秦兰萍,吴兆苏.中国35~64岁人群胆固醇水平与10年心血管病发病危险的前瞻性研究[J].中华心血管病杂志,2006,34(2):169-173. 被引量:133

二级参考文献11

  • 1吴桂贤,吴兆苏,王薇,刘静,孙佳艺,刘军,赵冬.1992—2002年北京一组队列人群心血管病危险因素变化趋势研究[J].中华心血管病杂志,2005,33(8):748-753. 被引量:53
  • 2World Health Organization.Multination monitoring of treads and determinants in cardiovascular disease (MONICA project) and manual of operation.Cardiovascular Disease Unit,Geneva,1993.
  • 3Wilson Peter WF,Agostino RBD,Levy D,et al.Prediction of coronary heart disease using risk factor categories (Framingham),Circulation,1998,97:1837-1847.
  • 4National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ).Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Ⅲ) final report.Circulation,2002,106:3143-3421.
  • 5Leppala JM,Virtamo J,Fogelholm R,et al.Different risk factors for different stroke subtypes:association of blood pressure,cholesterol,and antioxidants.Stroke,1999,30:2535-2540.
  • 6Zhang X,Patel A,Horibe H,et al.Cholesterol,coronary heart disease,and stroke in the Asia Pacific region.Int J Epidemiol,2003,32:563-572.
  • 7Kuulasmaa K,Pedoe TH,Dobson A,et al.Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations.Lancet,2000,355:675-687.
  • 8Eastern Stroke and Coronary Heart Disease Collaborative Research Group.Blood pressure,cholesterol,and stroke in eastern Asia.Lancet,1998,352:1801-1807.
  • 9Verschuren WM,Jacobs DR,Bloemberg BP,et al.Serum total cholesterol and long-term coronary heart disease mortality in different cultures.Twenty-five-year follow-up of the seven countries study.JAMA,1995,274:131-136.
  • 10Critchley J,Liu J,Zhao D,et al.Explaining the increase in coronary heart disease mortality in Beijing 1984 and 1999.Circulation,2004,110:1236-1244.

共引文献511

同被引文献17

  • 1戚文航.血管紧张素受体拮抗剂与心房颤动[J].中华心血管病杂志,2004,32(11):1042-1043. 被引量:93
  • 2Shiroshita-Takeshita A,Brundel BJ,Nattel S.Aattel fibrillation:Basic mechanisms,remodeling and triggers[J].J Interv Card Electrophysiol,2005,13(3):181-193.
  • 3Aviles RJ, Martin DO,Apperson-Hansen C,et al.Inflammation as a risk factor for atrial fibrillation[J].Circulation,2003,108(24):3006-3010.
  • 4Crandall MA,Horne BD,Day JD,et al.Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive Creactive protein incrementally and independently[J].Pacing Clin Electrophysiol,2009,32(5):648-652.
  • 5Yang Y,Li J,Lin X,et al.Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation[J].J Hum Genet,2009,54(5):277-283.
  • 6Abel T,Fehtr J.Role of rosuvastatin in current lipid-lowering therapy[J].Orv Hetil,2010,151(35):1424-1428.
  • 7Kalus JS,Coleman CI,White CM.The impact of suppressing the rennin-angiotensin system on atrial fibrillation[J].J Clin Pharmacol,2006,46(1):21-28.
  • 8Fauehier L,Pierre B,Labriotle A,et al.Antiarrhythmic effect of statin thorapy and atrial fibrillation a meta,analysis of randomized controlledtrials[J].J Am Coll Cardiol,2008,51(8):828-835.
  • 9孙益峰,梅运清,季强,王玺胜,冯靖,蔡建志,周永新,谢士梁.阿托伐他汀对冠状动脉旁路移植术后心房颤动的影响[J].中华医学杂志,2009,89(42):2988-2991. 被引量:8
  • 10玄春花,杨光,于治利.瑞舒伐他汀对慢性心力衰竭患者心房颤动的预防作用[J].中华老年心脑血管病杂志,2010,12(5):470-470. 被引量:12

二级引证文献47

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部